CRIS Current Research Information System

PICCALUGA, PIER PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.747
EU - Europa 10.938
AS - Asia 4.325
AF - Africa 562
SA - Sud America 25
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 6
Totale 27.617
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.703
IT - Italia 3.668
GB - Regno Unito 2.598
CN - Cina 1.840
SE - Svezia 1.214
DE - Germania 1.117
SG - Singapore 980
VN - Vietnam 701
UA - Ucraina 556
IN - India 500
RU - Federazione Russa 365
FR - Francia 364
IE - Irlanda 363
ZA - Sudafrica 220
EE - Estonia 173
TG - Togo 169
CH - Svizzera 144
CI - Costa d'Avorio 105
IR - Iran 78
FI - Finlandia 75
JO - Giordania 73
BG - Bulgaria 61
NL - Olanda 44
BE - Belgio 43
CA - Canada 42
GR - Grecia 38
SC - Seychelles 35
HR - Croazia 26
NG - Nigeria 26
JP - Giappone 24
ID - Indonesia 22
TR - Turchia 22
LB - Libano 19
LU - Lussemburgo 19
HK - Hong Kong 16
RO - Romania 14
BR - Brasile 10
KR - Corea 10
AU - Australia 9
ES - Italia 9
CL - Cile 8
CZ - Repubblica Ceca 6
SK - Slovacchia (Repubblica Slovacca) 6
UZ - Uzbekistan 6
AL - Albania 5
NZ - Nuova Zelanda 5
PH - Filippine 5
PL - Polonia 5
PT - Portogallo 5
AT - Austria 4
HU - Ungheria 4
IL - Israele 4
MY - Malesia 4
AE - Emirati Arabi Uniti 3
BD - Bangladesh 3
PE - Perù 3
RS - Serbia 3
SA - Arabia Saudita 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
DK - Danimarca 2
EC - Ecuador 2
EG - Egitto 2
EU - Europa 2
KZ - Kazakistan 2
MD - Moldavia 2
UG - Uganda 2
XK - ???statistics.table.value.countryCode.XK??? 2
AR - Argentina 1
AZ - Azerbaigian 1
BO - Bolivia 1
CR - Costa Rica 1
ET - Etiopia 1
GE - Georgia 1
GH - Ghana 1
IS - Islanda 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
LT - Lituania 1
LV - Lettonia 1
MT - Malta 1
PA - Panama 1
PK - Pakistan 1
SI - Slovenia 1
Totale 27.617
Salva come PNG Salva come JPEG
Città #
Southend 2.358
Fairfield 1.582
Chandler 939
Ashburn 923
Singapore 862
Houston 785
Woodbridge 759
Seattle 705
Wilmington 702
Cambridge 575
Princeton 574
Ann Arbor 515
Dong Ket 450
Santa Clara 429
Dublin 356
Milan 319
Jacksonville 299
Boardman 298
Nanjing 264
Rome 254
Padova 249
Westminster 238
Bologna 225
Lomé 169
Jinan 132
Berlin 130
Shenyang 128
Saint Petersburg 127
Bern 119
Beijing 117
Bremen 111
Hebei 107
Turin 107
Abidjan 105
New York 101
Naples 100
Nanchang 85
Changsha 84
Mülheim 82
San Diego 77
Amman 73
Helsinki 69
Florence 66
Parma 61
Sofia 61
Tianjin 61
Medford 60
Jiaxing 56
Guangzhou 49
Verona 44
Hangzhou 43
Falls Church 41
Haikou 41
Hyderabad 41
Zhengzhou 41
Redwood City 40
Brussels 39
Taizhou 38
Dearborn 35
Ningbo 34
Mahé 33
San Venanzo 32
Taiyuan 31
Palermo 30
Shanghai 30
Norwalk 29
Olalla 29
Toronto 27
Fuzhou 26
Abeokuta 25
Phoenix 25
Cagliari 24
Los Angeles 22
Catania 21
Jakarta 21
Tokyo 21
Wuhan 21
London 20
Redmond 20
Frankfurt am Main 19
Salsomaggiore Terme 19
Bari 18
Brescia 18
Pavia 18
Bühl 17
Lanzhou 17
Como 16
Des Moines 16
Fremont 16
Modena 16
Tehran 16
Leawood 15
Paris 15
Shenzhen 14
Dudelange 13
Istanbul 13
Kunming 13
Ravenna 13
San Francisco 13
Venice 13
Totale 18.349
Salva come PNG Salva come JPEG
Nome #
Linfomi non Hodgkin di derivazione dai linfociti T-periferici. 1.685
Instillazione diretta intranasale di amfotericina B liposomiale nella terapia delle micosi nasali. 552
Linfomi non Hodgkin di derivazione dai linfociti T-periferici. 426
Leucemia Acuta Linfoide. 329
Biology and treatment of follicular lymphoma. 221
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 218
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 213
ANALYSIS OF THE CODING GENOME OF SPLENIC MARGINAL ZONE LYMPHOMA REVEALS MUTATIONAL ACTIVATION OF NOTCH2 AND OTHER PATHWAYS REGULATING MARGINAL ZONE DIFFERENTIATION 208
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 184
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 179
Advances in the treatment for haematological malignancies. 175
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 173
The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies 167
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 166
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance 164
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 164
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 163
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 158
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification? 155
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 153
IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia 152
Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified 152
A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. 151
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation. 148
Expression of CD52 in peripheral T-cell lymphoma. 148
FIRMA MOLECOLARE E SUOI USI COME AGENTE DIAGNOSTICO 147
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma 145
Conditioning regimens in acute myeloid leukemia. 144
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 143
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 143
IFI16 expression is related to selected transcription factors during B-cell differentiation 142
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 139
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 139
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 138
Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation 137
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis 136
BCL10 down-regulation in peripheral T-cell lymphomas. 136
Pathobiologic Roles of Epstein-Barr Virus-Encoded MicroRNAs in Human Lymphomas 136
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 134
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma 134
An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. 133
Chronic inflammation, including Autoimmunity, and Lymphomagenesis. 133
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 132
Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature 132
Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. 130
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 130
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 127
Linfomi a cellule T periferiche NAS: nuovo indice prognostico. 127
Epstein-Barr Virus-Induced Metabolic Rearrangements in Human B-Cell Lymphomas 127
Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy 126
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. 126
The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: adipophilin. 126
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition 126
Pathobiology of hodgkin lymphoma. 126
Molecular genetics of peripheral T-cell lymphomas 125
Clonality analysis of immunoglobulin gene rearrangement by next-generation sequencing in endemic burkitt lymphoma suggests antigen drive activation of bcr as opposed to sporadic burkitt lymphoma 125
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 124
Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome 124
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 123
SNPs Array Karyotyping in Non-Hodgkin Lymphoma 123
Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma 122
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 122
Primary effusion lymphoma associated with Human Herpes Virus-8 and Epstein Barr virus in an HIV-infected woman from Kampala, Uganda: a case report. 122
MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN LYMPHOMAS WITHIN THE FIL (FONDAZIONE ITALIANA LINFOMI) MRD NETWORK: INTER-LABORATORY REPRODUCIBILITY ON BORDERLINE SAMPLES 122
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 122
Frequent Elevation of Akt Kinase Phosphorylation in Blood Marrow and Peripheral Blood Mononuclear Cells from High Risk myelodysplastic Syndrome Patients 121
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 121
The cell of origin of Burkitt lymphoma: germinal centre or not germinal centre? 121
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study 121
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 120
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 120
Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion. 119
Prognostic markers in peripheral T-cell lymphoma. 119
Pathobiology of anaplastic large cell lymphoma. 119
Targeted molecular therapy in peripheral T-cell lymphomas 119
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups 119
Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus 119
Pathobiology of Epstein-Barr virus-driven peripheral T-cell lymphomas 118
Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. 118
Molecular profiling of aggressive lymphomas 117
MicroRNAs sequencing unveils distinct molecular subgroups of plasmablastic lymphoma 117
Increased angiogenesis seems to correlate with inferior overall survival in myeloid sarcoma patients 117
The Prognostic value of tumor and microenvironment markers in classifical Hodgkin lymphoma (CHL) patients. 115
Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? 115
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 115
Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine 114
Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. 114
Duplex real-time polymerase chain reaction assay for the detection of human KIPyV and WUPyV in nasopharyngeal aspirate pediatric samples 113
Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome 112
Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda. 111
Resolving the diagnostic dilemma of T-cell clonal expansion after hematopoietic stem cell transplantation in T-cell lymphoma patients by TCR-gamma next generation sequencing 111
Hsa-miR-15a and Hsa-miR-16-1 Expression Is Not Related to Proliferation Centers Abundance and Other Prognostic Factors in Chronic Lymphocytic Leukemia 111
The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis 110
Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. 110
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma 109
Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas 109
Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy? 107
Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. 107
Preferential usage of specific immunoglobulin heavy chain variable region genes with unmutated profile and advanced stage at presentation are common features in patients with chronic lymphocytic leukemia from Senegal 107
Gamma-delta T-cell lymphomas. 106
Totale 15.873
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.315
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.315
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.813 0 0 0 0 0 0 836 832 888 424 346 487
2020/20213.738 755 274 209 170 99 209 79 174 377 209 195 988
2021/20224.459 353 178 292 365 443 293 95 280 219 372 906 663
2022/20235.170 643 709 254 660 313 388 166 268 865 142 456 306
2023/20242.212 124 250 121 171 152 300 172 179 92 187 199 265
2024/20253.280 327 869 479 416 834 296 59 0 0 0 0 0
Totale 28.228